Technology Insight: transcoronary ablation of septal hypertrophy
Haran Burri and Ulrich Sigwart*
Correspondence *Cardiology Service, University Hospital, 1211 Geneva 14, Switzerland
Email ulrich.sigwart@hcuge.ch
Outflow tract obstruction affects 5-10% of hypertrophic cardiomyopathy patients. Although myectomy is the gold standard treatment, alcohol septal ablation has emerged as an alternative nonsurgical procedure. Burri and Sigwart present a round up of the past 10 years' experience and discuss the pros and cons of this procedure.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cre-constructing the heartNature Genetics News and Views (01 Jan 2003)
Etiologies of cardiomyopathy and heart failureNature Medicine News and Views (01 Mar 1999)
